Further investigations involving DEXs engineered with HCC-targeting peptides, AFP, and immune adjuvants (DEXP&A2&N) to promote the recruitment and activation of DCs demonstrated complete tumor eradication in orthotopic HCC mice by activating both innate and adaptive immunity52. This evidence concerns the gene AFP and hepatocellular carcinoma.